United Therapeutics officer proposes $4.69M sale
The notice also records six earlier sales of 8,300 shares each from July 2 through September 17, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
United Therapeutics officer Paul Mahon reported a proposed sale of 8,300 common shares on October 1, 2026. The notice gives an aggregate market value of $4,689,050.97 and names Morgan Stanley Smith Barney LLC as broker. The shares are listed as acquired from the issuer that day through a stock option exercise, with cash payment. The notice also lists six prior sales from July 2 through September 17, 2026, each for 8,300 shares.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What gross proceeds were listed for Paul Mahon’s recent UTHR sales?
AI-generated analysis. How Rhea-AI works. Not financial advice.